Skip to content
2 minutes

MDxHealth is a front runner in epigenetic research with a proven track record of identifying, developing, validating and delivering molecular diagnostic assays. They provide functional genomic data that can be used for personalised cancer risk assessment, with specific focus on prostate cancer.

TeamworkProject 1 overview: Molecular diagnostic assay modeling

BioLizard assisted with development and optimisation of a robust model to calculate patient risk score for prostate cancer based on clinical biomarkers and other clinical features.

 

Wet lab

Project 2 overview: Molecular diagnostic triplex assay QC optimisation

The goal was to optimize current qualification of reagents and equipment. Instead of a head-to-head approach, we developed a QC panel that can be used in each run to see if they fall in between the expected QC ranges.

We were very pleased with the work BioLizard did. The BioLizard team were very flexible and took the necessary time to fully understand our needs. Their tailored service allowed us to draw meaningful conclusions from our data.” 


- MDxHealth

 

Our approach

Molecular diagnostic assay model

  • Model building to optimize clinical assay and patient risk score predictions.
  • Write SOPs.
  • Calculate performance on clinical cohorts.

Molecular diagnostic triplex assay QC optimisation

  • Based on historical data, develop expected range to be used as QC range.
  • Develop criteria for releasing new items (new reagent batch and/or equipment).
  • For day-to-day QC: Analyze calibrator values, generate expected range + compare different setups.

Results

SOPs

 

Provided detailed SOPs.

 

QC

 

Day–to-day QC with robust ranges for better reproducibility. Quality with less time, waste, and reagents.

 

For more information contact us today!

Work was performed in collaboration with MDxHealth.

mdxhealth-logo

Recommended Reading